These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

497 related items for PubMed ID: 16929363

  • 1. Biologic actions and therapeutic potential of the proglucagon-derived peptides.
    Drucker DJ.
    Nat Clin Pract Endocrinol Metab; 2005 Nov; 1(1):22-31. PubMed ID: 16929363
    [Abstract] [Full Text] [Related]

  • 2. [Glucagon-like peptides--synthesis, biological actions and some clinical implications].
    Otto Buczkowska E, Dworzecki T.
    Przegl Lek; 2004 Nov; 61(9):947-50. PubMed ID: 15803906
    [Abstract] [Full Text] [Related]

  • 3. Synthesis, secretion and biological actions of the glucagon-like peptides.
    Lovshin J, Drucker DJ.
    Pediatr Diabetes; 2000 Mar; 1(1):49-57. PubMed ID: 15016242
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The biology of incretin hormones.
    Drucker DJ.
    Cell Metab; 2006 Mar; 3(3):153-65. PubMed ID: 16517403
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.
    D'Alessio DA, Vahl TP.
    Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E882-90. PubMed ID: 15140755
    [Abstract] [Full Text] [Related]

  • 8. Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2.
    Baggio LL, Drucker DJ.
    Best Pract Res Clin Endocrinol Metab; 2004 Dec; 18(4):531-54. PubMed ID: 15533774
    [Abstract] [Full Text] [Related]

  • 9. Incretins and other peptides in the treatment of diabetes.
    Todd JF, Bloom SR.
    Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of glucagon secretion.
    Young A.
    Adv Pharmacol; 2005 Mar; 52():151-71. PubMed ID: 16492545
    [Abstract] [Full Text] [Related]

  • 11. The physiological role of GLP-1 in human: incretin, ileal brake or more?
    Schirra J, Göke B.
    Regul Pept; 2005 Jun 15; 128(2):109-15. PubMed ID: 15780430
    [Abstract] [Full Text] [Related]

  • 12. Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats.
    Lee Y, Kwon MK, Kang ES, Park YM, Choi SH, Ahn CW, Kim KS, Park CW, Cha BS, Kim SW, Sung JK, Lee EJ, Lee HC.
    J Gene Med; 2008 Mar 15; 10(3):260-8. PubMed ID: 18085721
    [Abstract] [Full Text] [Related]

  • 13. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition.
    Nagakura T, Yasuda N, Yamazaki K, Ikuta H, Tanaka I.
    Metabolism; 2003 Jan 15; 52(1):81-6. PubMed ID: 12524666
    [Abstract] [Full Text] [Related]

  • 14. Proglucagon-derived peptides: mechanisms of action and therapeutic potential.
    Sinclair EM, Drucker DJ.
    Physiology (Bethesda); 2005 Oct 15; 20():357-65. PubMed ID: 16174875
    [Abstract] [Full Text] [Related]

  • 15. Biological actions and therapeutic potential of the glucagon-like peptides.
    Drucker DJ.
    Gastroenterology; 2002 Feb 15; 122(2):531-44. PubMed ID: 11832466
    [Abstract] [Full Text] [Related]

  • 16. Oligofructose promotes satiety in rats fed a high-fat diet: involvement of glucagon-like Peptide-1.
    Cani PD, Neyrinck AM, Maton N, Delzenne NM.
    Obes Res; 2005 Jun 15; 13(6):1000-7. PubMed ID: 15976142
    [Abstract] [Full Text] [Related]

  • 17. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.
    Meier JJ, Gethmann A, Nauck MA, Götze O, Schmitz F, Deacon CF, Gallwitz B, Schmidt WE, Holst JJ.
    Am J Physiol Endocrinol Metab; 2006 Jun 15; 290(6):E1118-23. PubMed ID: 16403774
    [Abstract] [Full Text] [Related]

  • 18. Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.
    Deacon CF, Holst JJ.
    Int J Biochem Cell Biol; 2006 Jun 15; 38(5-6):831-44. PubMed ID: 16242377
    [Abstract] [Full Text] [Related]

  • 19. Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes.
    Hui H, Zhao X, Perfetti R.
    Diabetes Metab Res Rev; 2005 Jun 15; 21(4):313-31. PubMed ID: 15852457
    [Abstract] [Full Text] [Related]

  • 20. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans.
    Meier JJ, Nauck MA, Pott A, Heinze K, Goetze O, Bulut K, Schmidt WE, Gallwitz B, Holst JJ.
    Gastroenterology; 2006 Jan 15; 130(1):44-54. PubMed ID: 16401467
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.